Drug Trial Radar · NCT07300267
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Jan 13, 2026
Primary completion
Oct 24, 2028
Study completion May 25, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.
Conditions
- Pneumococcal Infection
Interventions
V118C (Stage 1)Biological
IM administration of V118C
V118C (Stage 2)Biological
IM administration of V118C
PCV20 (Stage 1)Biological
IM administration of PCV20
PCV20 (Stage 2)Biological
IM administration of PCV20
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Percentage of Participants With Immediate Adverse Events (AEs) Following VaccinationTime frame: Up to approximately 30 minutes postvaccination
- Stage 1: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)Time frame: Up to approximately 7 days postvaccination
- Stage 1: Percentage of Participants With Solicited Systemic AEsTime frame: Up to approximately 7 days postvaccination
- Stage 1: Percentage of Participants With Unsolicited Systemic or Injection-Site AEsTime frame: Up to approximately 28 days postvaccination
- Stage 1: Percentage of Participants With Serious Adverse Events (SAEs)Time frame: Up to approximately 12 months postvaccination
- Stage 1: Percentage of Participants With Medically Attended AEs (MAAEs)Time frame: Up to approximately 12 months postvaccination
- Stage 2: Percentage of Participants With Immediate AEs Following VaccinationTime frame: Up to approximately 30 minutes after each vaccination
- Stage 2: Percentage of Participants With Solicited Injection-Site AEsTime frame: Up to approximately 7 days after each vaccination
- Stage 2: Percentage of Participants With Solicited Systemic AEsTime frame: Up to approximately 7 days after each vaccination
- Stage 2: Percentage of Participants With Unsolicited Systemic or Injection-Site AEsTime frame: Up to approximately 28 days after each vaccination
- Stage 2: Percentage of Participants With SAEsTime frame: Up to approximately 12 months postdose 4
- Stage 2: Percentage of Participants With MAAEsTime frame: Up to approximately 12 months postdose 4
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Madera Family Medical Group ( Site 1004)
Madera, California · Recruiting
Acevedo Clinical Research Associates ( Site 1029)
Miami, Florida · Recruiting
University of South Florida-Department of Pediatrics ( Site 1002)
Tampa, Florida · Recruiting
Cotton O'Neil Research Center ( Site 1039)
Topeka, Kansas · Recruiting
University of Louisville, Norton Children's Research Institute ( Site 1005)
Louisville, Kentucky · Recruiting
The Pediatric Center ( Site 1025)
Columbia, Maryland · Recruiting
Saint Louis University Center for Vaccine Development ( Site 1031)
St Louis, Missouri · Recruiting
Child Health Care Associates ( Site 1035)
East Syracuse, New York · Recruiting
Carolina Family Care ( Site 1021)
Charleston, South Carolina · Recruiting
Tribe Clinical Research, LLC-Pediatrics ( Site 1008)
Greenville, South Carolina · Recruiting
Tribe Clinical Research - Spartanburg ( Site 1001)
Spartanburg, South Carolina · Recruiting
Epic Medical Research - Carrollton ( Site 1038)
Carrollton, Texas · Recruiting
Epic Medical Research- Garland ( Site 1017)
Garland, Texas · Recruiting
University of Texas Medical Branch ( Site 1020)
League City, Texas · Recruiting
Pediatric Research of Charlottesville, LLC ( Site 1012)
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.